What condition may result due to hyperglycemia associated with Terbutaline administration?

The condition resulting from hyperglycemia associated with Terbutaline administration is hypokalemia. Terbutaline is a beta-agonist medication commonly used as a tocolytic agent to prevent preterm labor. It can stimulate glycogenolysis and gluconeogenesis, leading to an increase in blood glucose levels. As blood glucose rises, insulin secretion is also stimulated, which causes potassium to shift from the extracellular space into the cells. This shift can result in a decrease in serum potassium levels, creating a state of hypokalemia.

Given the role of Terbutaline in altering glucose metabolism and its subsequent effect on potassium homeostasis, the connection between hyperglycemia from Terbutaline use and hypokalemia is well-established in medical literature. Understanding this relationship is essential in managing patients receiving such therapy, as electrolyte imbalances can have significant consequences.

Other options like hypocalcemia, macrosomia, and dehydration, while related to different clinical scenarios, do not directly stem from the hyperglycemic effects of Terbutaline in the same manner that hypokalemia does. Hypocalcemia typically involves calcium metabolism disorders, macrosomia is related to excessive fetal growth often seen in diabetic pregnancies, and dehydration is generally linked to fluid loss rather than the